Harrow

Harrow

Pharmaceuticals
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.

$1.4B

Market Cap • 9/10/2026

2006

(20 years)

Founded

2007

(19 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

90,2

P/S

5

P/EBITDA

71,9

P/OCF

219,3

P/FCF

273,4

P/E

BVPS

0,4

EPS

Market Cap

Market Cap

1,4B

EV

1,6B

EV/Revenue

5,8

EV/EBITDA

83,2

EV/EBIT

-577,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0,9%

Total Yield

0,9%

Payout

0%

Retained Earnings

-201,4M

Profitability

Gross Margin

73,3%

EBITDA Margin

6,9%

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

10,5%

Capex/Revenue

0,4%

Capex/D&A

5,7%

Capex/OCF

19,8%

SBC/OCF

235,1%

% PPE

2,5%

% Goodwill

0,1%

ROE

ROIC

Growth

CAGR Revenue 5Y

34,5%

CAGR OCF 5Y

-10,3%

Leverage

N.D./EBITDA

11,4

Debt/Equity

0%

Current Ratio

2,2

Quick Ratio

2

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium